Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 3

2(28.6%)

N/A

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(3)

Phase 3(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06836492Phase 3Recruiting

A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

Role: lead

NCT06710821Phase 1Not Yet Recruiting

Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

Role: lead

NCT06514313Phase 2Recruiting

Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

Role: lead

NCT06451302Not ApplicableActive Not Recruiting

Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study

Role: lead

NCT05338541Phase 1Recruiting

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.

Role: lead

NCT06208917Phase 3Recruiting

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Role: lead

NCT05076071Unknown

Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors

Role: lead

NCT04659733Phase 1Unknown

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Role: lead

All 8 trials loaded